Management

Per Andersson

Chief Executive Officer

Chief Executive Officer at Xspray Pharma since 2006
Born 1967

Per Andersson has been the CEO of Xspray Pharma AB since 2006. Per Andersson has extensive experience from the medical industry, especially within patent work and strategies. Previous positions include Science Director at Gyros AB and Scientist at GE Healthcare

Education: Ph.D. in Analytical Chemistry, Stockholm university

Other current activities: Chairman of the board of Robotic Lawn Care Sweden AB and Xspray Pharma Futurum AB and deputy board member in Journeyman Stockholm AB

Previous assignments (recent 5 years): –

Holdings: 200,260 shares and 61,186 options of which 33,062 warrants and 28,124 employee stock options

Independent in relation to the larger shareholders but not in relation to the company

Kerstin Hasselgren

Chief Financial Officer

Chief Financial Officer at Xspray Pharma since 2019
Born 1961

Kerstin Hasselgren has broad experience from working in large public international companies as VP Corporate Business Control at SSAB, CFO at Alstom Transport Nordic, VP Finance Global Operations at AstraZeneca and VP Finance Global R&D at AstraZeneca

Education: M.Sc. Business Administration, Stockholm School of Economics

Other current activities: Member of the Board of Synact Pharma

Previous assignments (the recent 5 years): None

Holdings in the Company: 5,500 shares and 92,288 options of which 69,788 warrants and 22,500 employee stock options

Independent in relation to major shareholders but not in relation to the Company

Anna-Karin Ekberg

Senior Vice President, Global Head Marketing & Sales

Senior Vice President, Global Head Marketing & Sales since March 2022
Born 1966

Anna-Karin Ekberg has more than 25 years of experience from various management positions in the pharma industry. Her experience reaches from Nordic to international/HQ global positions and from small biotech to big pharma. Anna-Karin launched Glivec.
She has previously held positions with Schering AG, Novartis, HRA Pharma, Ariad, Aprea, Norgine and Oncopeptides.

Education: Bachelor of science in Diagnostic Radiology and Nursing Science, Uppsala University, DIHM Business School, Stockholm

Other current activities: CEO/owner TAKE-Life Science & Business partner AB and collaboration with STILLE AB – product STILLE-Ekberg Ergo Scissors

Previous assignments (the recent 5 years): Board member Picture my Life AB

Holdings in the Company: 25,311 options of which 8,437 warrants and 16,874 employee stock options

Independent in relation to major shareholders but not in relation to the Company

Andreas Konar

Senior Vice President Business Development

Senior Vice President Business Development at Xspray since 2010
Born 1949

Andreas Konar has 4 decades of experience from the pharmaceutical industry in R&D, clinical research, project management and business development. He has been VP R&D at Dumex and AL Pharma, responsible for the Drug Delivery Business Unit at LifeCycle Pharma, business development at Recordati and section manager at Astra Draco

Education: Associate Professor in Organic Chemistry, University of Lund, Sweden
Ph.D. in Organic Chemistry, University of Lund, Sweden
M.Sc. in Chemical Engineering, Chalmers University of Technology, Gothenburg, Sweden

Other current activities: Member of the Board of Ground Zero Pharmaceuticals, Irvine, CA, USA

Previous assignments (recent 5 years): None

Holdings in the Company: 73,555 shares, 13,500 warrants

Independent in relation to major shareholders but not in relation to the Company

Charlotta Liljebris

Senior Vice President Research and Development

Senior Vice President Research and Development at Xspray Pharma since 2018
Born 1964

Charlotta Liljebris has 30 years of experience from the pharmaceutical industry. She has been responsible for the project portfolio and business development at Orexo, VP R&D at Aprea with focus on oncology and worked in several leading positions within project management at Biovitrum.

Education: Ph.D. in Medicinal Chemistry, Uppsala University, Sweden
M.Sc. in Chemistry, Uppsala University, Sweden

Other current activities: Deputy board member in Liljebris Consulting AB

Previous assignments (the recent 5 years): Member of the Board in Recipharm OT Chemistry, Connect Uppsala and Sprint Bioscience

Holdings in the Company: 2,000 shares and 38,814 options of which 21,938 warrants and 16,876 employee stock options

Independent in relation to major shareholders but not in relation to the Company.

Thomas Walz

Chief Medical Officer

Chief Medical Officer at Xspray Pharma since September 2022

Born 1960

Thomas was previously the Head of Department of Oncology at Karolinska University Hospital and has extensive experience in from the pharmaceutical industry. He most recently joins from the position as the Nordic Medical Director of Oncology at GSK.

Education: Associate professor in Oncology at Linköping University and an MBA degree from Stockholm School of Economics

Other current activities: None

Previous assignments (recent 5 years): None

Holdings: 25,311 options of which 8,437 warrants and 16,874 employee stock options

Independent in relation to the larger shareholders but not in relation to the company